Mark Woyshville, MD
Psychiatry · Middleburg Heights, OHNPI 1275612848
Payments from drug & device makers
Across 702 payments — averaging $3092.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$1.3M
- Otsuka Pharmaceutical Development & Commercialization, Inc.$254K
- AbbVie$221K
- Genentech, Inc.$109K
- Avanir Pharmaceuticals, Inc.$71K
- Boehringer Ingelheim$68K
- plus $152K from 33 others
Across 38 payments — averaging $4200.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$94K
- Orexo US, Inc.$61K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$4K
- Purdue Pharma L.p.$503
What the payments were for
- Consulting fees$9,3187%
- Speaking & faculty fees$103,06478%
- Travel & lodging$6,4735%
- Food & beverage$12,98010%
- Education$1600%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$60,737
- UZEDY$20,614
- CAPLYTA$14,854
- QUVIVIQ$14,087
- Dayvigo$2,280
- LYBALVI$1,849
- REXULTI$1,152
- INVEGA TRINZA$246
- COBENFY$244
- Auvelity$244
- INVEGA SUSTENNA$234
- ABILIFY ASIMTUFII$138
- Fanapt$125
- AUSTEDO$119
- QELBREE$110
How this compares
$2,170,797 in reported general payments places this provider in the 95th percentile of 1,119 psychiatry providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| WakixPitolisant Hcl | 25 | $347,056 |
| IngrezzaValbenazine Tosylate | 41 | $317,204 |
| SpravatoEsketamine Hcl | 108 | $233,179 |
| VraylarCariprazine Hcl | 69 | $106,714 |
| AristadaAripiprazole Lauroxil | 13 | $36,408 |
| Abilify MaintenaAripiprazole | 13 | $33,216 |
| AuvelityDextromethorphan Hbr/Bupropion | 21 | $22,507 |
| Clozapine OdtClozapine | 27 | $15,760 |
| TrintellixVortioxetine Hydrobromide | 26 | $14,687 |
| BelsomraSuvorexant | 27 | $12,395 |
| Lurasidone Hcl | 30 | $12,111 |
| LinzessLinaclotide | 12 | $11,163 |
| VyvanseLisdexamfetamine Dimesylate | 18 | $8,095 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 47 | $6,072 |
| FetzimaLevomilnacipran Hcl | 12 | $6,055 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Harmony Biosciences LLCWakix | $41,868 | $347,05625 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $307 | $317,20441 claims |
| Johnson & JohnsonSpravato | $793 | $233,179108 claims |
| AbbVieVraylar, Linzess, Fetzima | $220,967 | $123,93293 claims |
| Alkermes, Inc.Aristada | $1,235 | $36,40813 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $969 | $33,21613 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $221 | $22,78144 claims |
| Axsome Therapeutics, Inc.Auvelity | $681 | $22,50721 claims |
| MerckBelsomra | $134 | $12,39527 claims |
| Hikma Pharmaceuticals USABuprenorphine-Naloxone | $503 | $6,07247 claims |
| Eisai Inc.Dayvigo | $2,445 | $5,98818 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $14,317 | $5,36212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,119 psychiatry providers in Ohio.
Other psychiatry in Middleburg Heights
- Shishuka MalhotraCanton$15M
- Henry NasrallahCincinnati$3.8M
- Otto DuenoDayton$3.1M
- Diab AlmhanaAvon Lake$2.7M
- Mohamed Abdel AzizWest Chester$2.6M
- Fred RomeoColumbus$2.3M
- Amita PatelDayton$2.1M
- Caleb AdlerCincinnati$2M
- Richard SandersDayton$1.8M
- Pradeep ManudhaneCanton$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.